Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27885240 | 0.87 | DRD2 (0.54) | DRD2DRD3HTR1A | |
| SCHEMBL26251626 | 0.86 | — | — | |
| SCHEMBL16464076 | 0.86 | SLC6A2 (0.53) | DRD2DRD3HTR1A | |
| SCHEMBL12695907 | 0.86 | DRD2 (0.52) | DRD2DRD3HTR1A | |
| SCHEMBL14151352 | 0.86 | DRD2 (0.52) | DRD2DRD3HTR1A | |
| SCHEMBL14151320 | 0.86 | DRD2 (0.52) | DRD2DRD3HTR1A | |
| SCHEMBL16464078 | 0.86 | SLC6A2 (0.53) | DRD2DRD3HTR1A | |
| SCHEMBL16465017 | 0.86 | — | — | |
| SCHEMBL16464576 | 0.83 | HTR1A (0.60) | DRD2DRD3HTR1A | |
| SCHEMBL16464578 | 0.83 | HTR1A (0.60) | DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133334-A1 | NOVEL VDAC1 INHIBITORS | ABARCEO PHARMA AB (SE) | 2025-06-26 | — | — | WO | disclosed |
| CN-117402124-A | Aryl sulfonamide compound and anti-influenza application thereof | 中国医学科学院医药生物技术研究所 | 2024-01-16 | — | — | CN | disclosed |
| US-9353096-B2 | Substituted phenylcarbamate compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2906544-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| CN-104703973-A | Substituted phenyl carbamate compounds | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | disclosed |
| WO-2014056958-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| EP-0807111-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | DRD2 1425/4885DRD3 1226/4885HTR1A 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.